Skip to main content

Rebecca A Previs

Adjunct Assistant Professor in the Department of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
Division of Gynecologic Oncolo, DUMC Box 3079, Durham, NC 27710

Research Interests


Immune microenviroment in gynecologic malignancies, novel therapies for ovarian and uterine cancer, PARP inhibition in uterine cancer, molecular testing of gynecologic malignancies, early Phase clinical trials

Selected Grants


Experiences of Discrimination, Dysbiosis, and Racial Disparities in Ovarian Cancer

ResearchCo-Mentor · Awarded by National Institutes of Health · 2023 - 2028

Use of an oncolytic adenovirus to promote anti-tumor T-cell responses in ovarian cancer

ResearchMentor · Awarded by Foundation for Women's Cancer · 2022 - 2023

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023

Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy

ResearchPrincipal Investigator · Awarded by Ponce Health Sciences University · 2020 - 2022

Molecular classification of endometrial advanced stage cancers and association with survival outcomes: Ancillary analysis of GOG-0258

ResearchCo Investigator · Awarded by American Association of Obstetricians and Gynecologists Foundation · 2021 - 2022

Experiences of Discrimination, Dysbiosis, and Racial Disparities in Ovarian Cancer

ResearchCo-Mentor · Awarded by National Institutes of Health · 2023 - 2028

Use of an oncolytic adenovirus to promote anti-tumor T-cell responses in ovarian cancer

ResearchMentor · Awarded by Foundation for Women's Cancer · 2022 - 2023

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023

Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy

ResearchPrincipal Investigator · Awarded by Ponce Health Sciences University · 2020 - 2022

Molecular classification of endometrial advanced stage cancers and association with survival outcomes: Ancillary analysis of GOG-0258

ResearchCo Investigator · Awarded by American Association of Obstetricians and Gynecologists Foundation · 2021 - 2022

Are ESR1 mutations associated with shorter progression free survival in copy number-low endometrial adenocarcinomas?

ResearchCollaborating Investigator · Awarded by Foundation for Women's Cancer · 2020 - 2022

Immune modulation of CaMKK2 in the ovarian tumor microenvironment

ResearchPrincipal Investigator · Awarded by American Association of Obstetricians and Gynecologists Foundation · 2019 - 2020

Evaluation of homologous recombination deficiency in uterine serous cancer

ResearchPrincipal Investigator · Awarded by Myriad Genetics, Inc. · 2018 - 2019

Janet Burros Ovarian Cancer Repository

ResearchCo Investigator · Awarded by Cancer Data Initiative · 2018 - 2019

Fellowships, Gifts, and Supported Research


T32 Training Grant · 2013 - 2015 NCI-DHHS-NIH
Janet Burros Ovarian Cancer Repository in collaboration with the Cancer Data Initiative · 2018 Janet Burros Memorial Foundation
Molecular classification of medically managed endometrial tumors · 2018 Charles Hammond Research Fund · $10,000.00
Exploring the immune contexture of molecularly characterized uterine cancers · 2019 - 2022 PI · Goldman Sachs Philanthropy Fund/Emerson Collective Fund
Prospective randomized trial of streamlined genetic education and testing for ovarian, fallopian and peritoneal cancer patients · 2019 - 2021 Gray Foundation

External Relationships


  • LabCorp (Laboratory Corp of America)

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.